Regulatory Sanofi receives FDA approval for Tzield in paediatric diabetes Pharmaceutical Business ReviewThe approval expands the previous indication from those aged eight and above and was granted under a priority review process.RegulatoryMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaceutical Business Review The approval expands the previous indication from those aged eight and above and was granted under a priority review process. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: AbbVie opts for North Carolina to house $1.4bn manufacturing siteNext: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
